None

[Articles] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Addition of panitumumab to EOC chemotherapy does not increase overall survival and cannot be recommended for use in an unselected population with advanced oesophagogastric adenocarcinoma.

Vectibix panitumumab: Phase III data

Human medicines European Public Assessment Report (EPAR): Vectibix, panitumumab, Revision: 13, Authorised

Human medicines European Public Assessment Report (EPAR): Vectibix, panitumumab, Revision: 15, Authorised

Human medicines European Public Assessment Report (EPAR): Vectibix, panitumumab, Revision: 14, Authorised

Amgen announces top-line results of Vectibix® (panitumumab)

Study meets primary endpoint of non-inferiority in monotherapy setting...

Amgen-Beta JV Significant For China Medical Industry, Execs Say

Amgen-Beta Pharma, the joint venture formed recently by Beta Pharma and Amgen is far more ambitious than its initial focus on getting Vectibix (panitumumab) for colon cancer on China's market, company...

Vectibix holds its own against Erbitux in mCRC

Amgen's colorectal cancer treatment Vectibix (panitumumab) performed no worse than its older rival Erbitux (cetuximab) in a head-to-head study when used as a single agent for chemorefractory metastat...

Histological Complete Response after Neoadjuvant XELOX in Advanced Gastric Carcinoma.

SUMMARYWe report on a case of a 65-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with capecitabine and oxal...

A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.

PURPOSE: To compare the pharmacokinetics (PK) of bevacizumab (BV) at steady-state under two different dosing regimens, 7.5 mg/kg q3w and 5.0 mg/kg q2w, concomitantly with a combination of capecitabi...

Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab.

Panitumumab (ABX-EGF or Vectibix), the first fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR), was approved by the Food and Drug Administration for treatment of patien...

Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.

PURPOSE: To evaluate the efficacy, safety and quality of life of a short course of oxaliplatin plus capecitabine (XELOX) followed by single-agent capecitabine in patients with previously untreated, in...

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.

PURPOSE: Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line...